Corporate Representative's Report
IFCC Council Meeting Meeting
April 10, 2022

Joe Passarelli – Executive Board
Corporate Representative
Contact: joseph.passarelli@roche.com

Advancing excellence in laboratory medicine for better healthcare worldwide

This is not an authorized Roche presentation
The following corporate representatives are members of the Executive Committees of IFCC's operational units:

- **Scientific Division:**
  Michael Rottmann (Roche) (1st term Mar 2020-2022)

- **Emerging Technologies Division:**
  Peng Yin (Abbott) (2nd term 2021-2023)
  Markus Roessler (Roche) (2nd term 2021-2023)

- **Education & Management Division:**
  André Ziegler (Roche) (2nd term 2021-2023)

- **Communications & Publications Division:**
  Tricia Ravalico (Abbott) (2nd term 2021-2023)

- **Congresses & Conferences Committee:**
  Cheryl Jackson (Beckmann Coulter) (2nd term 2021-2023)

…and many more in
- Committees
- Working Groups
- Task Forces
IFCC Structure and Organization

IFCC Council
- Awards Committee
- Nominations Committee
- Special Projects
- Finance Committee
- Task Forces
- Congresses and Conferences Committee
- IFCC Office - Milan

Scientific Division
- Committees & Working Groups
  - Michael Rottmann, Roche Corporate Representative
    first 3 year term ends Dec. 2022

Education & Management Division
- Committees & Working Groups
  - Andre Ziegler, Roche Corporate Representative
    second 3 year term ends Dec. 2023

Communications & Publications Division
- Committees & Working Groups
  - Tricia Ravalico, Abbott Corporate Representative
    second 3 year term ends Dec. 2023

Emerging Technologies Division
- Committees & Working Groups
  - Markus Roessler, Roche Corporate Representative
    second 3 year terms ends Dec. 2023

IFCC Office
- Joe Passarelli, Roche Corporate Representative
  first 3 year term ends Dec. 2023
- Michael Rottmann, Roche Corporate Representative
  first 3 year term ends Dec. 2022
- Andre Ziegler, Roche Corporate Representative
  second 3 year term ends Dec. 2023
- Tricia Ravalico, Abbott Corporate Representative
  second 3 year term ends Dec. 2023
- Peng YIN, Abbott Corporate Representatives
  second 3 year terms ends Dec. 2023

IFCC Council
- Joe Passarelli, Roche Corporate Representative
  first 3 year term ends Dec. 2023
- Michael Rottmann, Roche Corporate Representative
  first 3 year term ends Dec. 2022
- Andre Ziegler, Roche Corporate Representative
  second 3 year term ends Dec. 2023
- Tricia Ravalico, Abbott Corporate Representative
  second 3 year term ends Dec. 2023
- Peng YIN, Abbott Corporate Representatives
  second 3 year terms ends Dec. 2023
Who are the current IFCC Corporate Members? (Status March 2022) *New in 2019-2022*

53 in total

Abbott (USA)  
Agappe Diagnostics Ltd (India)  
Asahi Kasei Pharma Corporation (Japan)  
Autobio Diagnostics (China)*  
BD Life Sciences (UK)  
Beckman Coulter (USA)  
The Binding Site Group (UK)  
Bio-Rad Laboratories (France)  
C.P.M. Diagnostic Research SAS (Italy)  
Diagnostica Stago (France)*  
DiaSorin (Italy)*  
Diasys (Germany)  
ET Healthcare (USA)  
Fujifilm Wako Pure Chemical Corp. (Japan)  
Fujirebio Europe (Belgium)  
Gentian AS (Norway)  
Helena Biosciences Europe (UK)  
Hemas Hospitals (Sri Lanka)  
HyTest Ltd. (Finland)  
Immunodiagnostic Systems (IDS) (UK)*  
Instrumentation Laboratory (IL), (USA)*  
JSC Megalab (Georgia)*  
LLP Labtronic (Kazakhstan)*  
LumiraDx (UK)*  
Maccura (China)  
MedicalSystem Biotechnology (China)

Medix Biochemica (Finland)*  
Menarini Diagnostics (Italy)  
Mindray Bio-Medical Electronics (China)  
Nittobo Medical (Japan)*  
Nova Biomedical Corporation (USA)  
Oneworld Accuracy Collaboration (Canada)  
Ortho-Clinical Diagnostics (UK)  
PHC Europe B.V. (ex Mitsubishi) (Germany)  
PerkinElmer (Finland)*  
Radiometer Medical (Denmark)  
Randox Laboratories (UK)  
Roche Diagnostics (Switzerland)  
Sebia (France)  
Sekisui Diagnostics (UK)  
Sentinel CH (Italy)  
Shanghai Kehua Bio-Engineering (China)  
Shanghai Zhicheng Biological Technology (China)  
Shenzen YHLO Biotech (China)*  
Siemens Healthcare Diagnostics (USA)  
Snibe (China)  
Synlab International (Germany)*  
Sysmex Europe (Germany)  
Technogenetics (Italy)*  
Thermo Fisher Scientific (Finland)  
Tosoh (Japan)*  
Labor Dr. Wisplinghoff (Germany)  
Wuhan Life Original Biotech Joint Stock (China)*
Advancing excellence in laboratory medicine for better healthcare worldwide
Where are most of the Corporate Members based?

- China (9)
- UK (8)
- USA (6)
- Germany and Italy (5)
- Japan and Finland (4)
- France (3)
IFCC Corporate Membership changes since 2014

New Corporate Members (28)

- Helena Biosciences Europe – 2015
- Ningbo Medicalsystem Biotechnology – 2015
- KHB Shanghai Kehua Bioengineering – 2016
- Beijing Dream Diagnostic Medicine (BDDC) – 2017
- Timedico – 2018
- Hemas Hospitals Ltd. – 2018
- ET Healthcare – 2019
- Nittobo Medical – 2019
- SCL Healthcare – 2019
- Immunodiagnostics Systems (IDS) – 2019
- Agilent – 2019
- Zhejiang Kuake Biotechnology – 2019
- LLP Labtronic – 2019
- Tosoh – 2020
- Wuhan Life Original Biotech Joint Stock – 2020
- Megalab – 2020
- LumiraDx – 2020
- Shenzhen YHLO Biotech – 2020
- Instrumentation Laboratory – 2020
- Technogenetics – 2021
- PerkinElmer – 2021
- Panasonic Healthcare EU (PHC-EU) (formerly Mitsubishi Chemical Europe GmbH) - Replaces Mitsubishi – 2021
- GenScript Biotech Corporation – 2021
- Autobio Diagnostics – 2021
- Medix Biochemica - 2021
- Diagnostica Stago – 2021
- Synlab International – 2022
- Diasorin - 2022

Cancellations (28 + 2)

- Biomerieux – 2014
- Perin Elmer – 2014
- Innotrac Diagnostic – 2014
- Immunodiagnostics Systems – 2014
- BG Medicine – 2014
- Dako – 2015
- Wiener – 2015
- Drew Scientific – 2015
- Labquality – 2015
- Care – 2015
- Scipac – 2015
- Phadia – 2015
- Biocrates – 2016
- Merck Millipore – 2016
- Elga Labwater – 2017
- Response Biomedical – 2017
- Sonic Healthcare Europe – 2017
- Philips – 2017
- Unilabs – 2017
- Axis Shield – 2018
- Guangzhou Wondfo Biotech – 2018
- Instrumentation Laboratory – 2018
- Analis – 2019
- SCL Healthcare – 2020
- PPD – 2020
- Zhejiang Kuake Biotechnology – 2020
- Timedico – 2020
+ 2 cancellations due to mergers
- GenScript Biotech Corporation - 2022

Stronger engagement & retention of Corporate Members is needed
Task Force Corporate Members (TF-CM) was initiated in 2019 to enhance collaboration and improve retention.
## Task Force Corporate Members (TF - CM)

### Full members
- **Tricia Ravalico** (Chair) (Abbott, USA)
- **Alessandro Ortisi** (Secretary) (Siemens Healthineers, Italy)
- **Jean-Sébastien Blanchet** (Member) (Beckman Coulter, France)
- **Vincent Chen** (Member) (Snibe, China)
- **Brendan Meyer** (Member) (Becton Dickinson, UK)
- **Andy Quintenz** (Member) (Bio-Rad Laboratories, USA)
- **Joe Passarelli** (Corp. Rep. at Executive Board) (Roche, USA)

### Corresponding members
- **Jan Gorka** Diasys
- **Maurizio Gramegna** Technogenetics
- **Gavin Tu** Maccura Biotechnology
- **Anne Skurup** Radiometer Medical ApS
- **Yan Liu** Mindray
- **Ivan Salgo** Ortho Clinical Diagnostics

**Corporate Representatives of the Divisions are invited as guests**

**Other interested persons can apply (one per company that has no full member)**
Mission of the Task Force Corporate Members

Objectives:

- To assist IFCC in promotion of science, innovation, and advancement of the essential contribution of laboratory medicine to health care
- To facilitate discussion among Corporate Members and identify common topics of interest and/or concern
- To improve the engagement of Corporate Members with the IFCC
- To serve as the “voice of industry” and be more accessible to all IFCC teams and leadership, enabling a more diverse understanding and appreciation of needs among corporate members and the IFCC
- To increase awareness with other Corporate Members of IFCC TF-CM and to encourage their participation in IFCC activities

Areas of Focus:

- The voice of corporate members within IFCC
- High impact and frequency of conferences/congresses
- Growth and sustainability of corporate members
- Effective, timely and enhanced communications among IFCC, Conference Organizing Secretariat, and Corporate Members
- Industry needs for IFCC involvement with regulators and clinical societies
Exploring where Corporate Members see value in IFCC membership

<table>
<thead>
<tr>
<th>IFCC Membership Value</th>
<th>Least attractive</th>
<th>Most attractive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Being brand associated with the global leading organization in Laboratory Medicine</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>Being able to hold key positions in IFCC Divisions and influence decision making processes of world leaders.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Being able to hold influential key positions in IFCC Working Groups, Committees and Task Forces</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Receiving all documents and publications of the IFCC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Receiving a 10-20% discount on exhibition fees at the EuroMedLab and WorldLab Congresses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Receiving a premium location on the exhibition floor at EuroMedLab and WorldLab Congresses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Receiving 25% discount on Advertising on eNews</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Access to world renown speakers and advisers in association with the IFCC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Being able to support awards, conferences, satellite symposia, and various educational activities in partnership with IFCC, further enhancing the visibility of your company to an ideal target audience</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Being able to elect, vote and/or represent the Corporate Representative to the Executive Board of IFCC, strengthening communication and collaboration between industry and laboratory professionals.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supporting and being involved in important standardization/harmonization of IVD products and services.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
TF-CM Survey Qualitative Questions:

1. What can IFCC do to enhance membership benefits to corporate members?

2. Has the overall value of being a corporate member of the IFCC increased, decreased, or stayed the same over the past year. If increased or decreased, please elaborate.

3. Has your company’s overall participation in IFCC committees, working groups, task forces, etc. increased, decreased, or stayed the same over the past year. If increased or decreased, please elaborate.

4. Are relevant members of your organization regularly aware of opportunities to partner with the IFCC? Yes, No, not to the extent desired?

5. Has your company’s interest and/or engagement with the IFCC increased, decreased, or stayed the same over the past year. If increased or decreased, please elaborate.

6. Do you believe the IFCC has increased, decreased, or stayed the same with respect to partnering with corporate members to influence laboratory medicine. If increased or decreased, please elaborate.

7. Please add any additional comments that have not already been addressed by the survey, especially any areas that can be improved.
How can IFCC become more attractive for Corporate Members?

- **By increasing awareness for the importance of lab testing** in general and providing education with focus on countries with limited resources.

- **By supporting**, together with clinical societies, **medical claims leading to reimbursement**.

- **By emphasizing the importance of quality and of standardization / harmonization** of testing, clinical pathways, reporting, result interpretation...

- **By co-operating** with other organizations (CLSI, ISO, FDA, regional federations, clinical societies, etc.) to secure **alignment of guidelines and recommendations** and **harmonization of global regulatory requirements**.

- **By becoming more active in IVDR and its implementation**.

- **By providing opportunities for exhibitions, industry symposia and networking** with lab professionals at high-level academic conferences, especially with hybrid or virtual formats.

- **By increasing participation** of Corporate Members at all levels.
The following persons are Corporate Members of the Congress Organizing Committees (COC):

- **IFCC-EFLM EuroMedLab 2022, April 10 - 14**
  Munich, Germany:
  Abir Alhelou (Abbott)

- **IFCC WorldLab 2022, June 26 - 30**
  Seoul, South Korea:
  Douglas Chung (Abbott)

- **IFCC-EFLM WorldLab + EuroMedLab 2023, May 21 - 25**
  Rome, Italy:
  Angel de la Fuente (Roche)
Next Corporate Members Meeting:

When: EuroMedLab Munich (in-person and with a virtual option)
Monday, April 11, 2022
11:30 – 13:30 local time
Thank you for your participation

For further information visit
www.ifcc.org | eacademy.ifcc.org